Qianjiang Yongan Pharmaceutical Co., Ltd.

SZSE:002365 Stock Report

Market Cap: CN¥2.5b

Qianjiang Yongan Pharmaceutical Valuation

Is 002365 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002365 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002365 (CN¥8.56) is trading above our estimate of fair value (CN¥0.74)

Significantly Below Fair Value: 002365 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002365?

Key metric: As 002365 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 002365. This is calculated by dividing 002365's market cap by their current revenue.
What is 002365's PS Ratio?
PS Ratio3.2x
SalesCN¥788.79m
Market CapCN¥2.49b

Price to Sales Ratio vs Peers

How does 002365's PS Ratio compare to its peers?

The above table shows the PS ratio for 002365 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.2x
301258 Suzhou Fushilai Pharmaceutical
6xn/aCN¥2.5b
300878 Zhejiang Wecome Pharmaceutical
5.8xn/aCN¥2.7b
300108 Ji Yao Holding Group
4.1xn/aCN¥1.5b
688189 Hunan Nucien Pharmaceutical
4.9xn/aCN¥2.0b
002365 Qianjiang Yongan Pharmaceutical
3.2xn/aCN¥2.5b

Price-To-Sales vs Peers: 002365 is good value based on its Price-To-Sales Ratio (3.2x) compared to the peer average (5.2x).

Price to Sales Ratio vs Industry

How does 002365's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
600664 Harbin Pharmaceutical Group
0.6xn/aUS$1.30b
000411 Zhejiang Int'l GroupLtd
0.2xn/aUS$790.12m
000153 Anhui Fengyuan Pharmaceutical
0.7xn/aUS$413.04m
600781 FUREN Group PharmaceuticalLtd
0.3xn/aUS$66.91m
002365 3.2xIndustry Avg. 3.6xNo. of Companies35PS02.85.68.411.214+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 002365 is good value based on its Price-To-Sales Ratio (3.2x) compared to the CN Pharmaceuticals industry average (3.6x).

Price to Sales Ratio vs Fair Ratio

What is 002365's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002365 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 002365's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Dong-E-E-JiaoLtd

CN¥36.7b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.18

7D

-1.8%

1Y

13.3%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.20

7D

-3.1%

1Y

-24.5%

Hunan Jiudian Pharmaceutical

CN¥11.8b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.80

7D

-1.8%

1Y

12.8%